Kristine Flemister and Tommy Bramley Provide Perspective on Financial Toxicity and Patient Support in PM360
September 8, 2020
The economic ripple effect of the COVID-19 pandemic is expected to have a significant impact on patient access to critical therapies, particularly for those managing chronic illnesses. As the industry navigates the road ahead, all stakeholders have a responsibility to support patients in getting the care they need. This includes taking steps to reduce instances of financial toxicity, which refers to the direct and indirect effects induced by the cost of managing a serious diagnosis, such as psychosocial distress, diminished patient outcomes, and poorer quality of life. Read more in a recent article from Krisitine Flemister, PharmD, President of Xcenda, and Tommy Bramley, PhD, President of Lash Group, in PM360.